Optimization and Validation of the Cationization Method for the Fab' Fragment of Antibody Rituximab

Area of Science:

• Biochemistry
• Pharmaceutical Analysis
• Protein Chemistry

Background:

• Rituximab is a crucial monoclonal antibody in cancer therapy.
• Accurate characterization of antibody fragments like Fab' is essential for quality control.
• Existing cationization methods require optimization for specific antibody fragments.

Purpose of the Study:

• To optimize and validate a cationization method for the rituximab antibody Fab' fragment.
• To ensure the method adheres to International Council for Harmonization (ICH) guidelines.
• To establish a reliable analytical approach for rituximab Fab' cationization.

Main Methods:

• Rituximab antibody fragmentation into F(ab)2 using pepsin.
• Reduction of F(ab)2 to Fab' fragments.
• Systematic optimization of cationization parameters (pH, time, reagents).
• Validation using spectrophotometry and the bromophenol blue (BPB) dye assay.
• Assessment of method linearity, robustness, and sensitivity.

Main Results:

• An optimized cationization protocol for rituximab Fab' fragments was successfully developed.
• The method demonstrated linearity, robustness, and sensitivity during validation.
• Spectrophotometric analysis using the BPB assay confirmed cationization efficiency.
• The optimized method provides a reliable approach for Fab' fragment analysis.

Conclusions:

• The optimized and validated cationization method is effective for rituximab Fab' fragments.
• This method supports robust quality control and characterization of antibody-based therapeutics.
• The study provides a standardized protocol applicable to similar biopharmaceutical analyses.